Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 2
2016 1
2021 2
2022 1
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Anti-seizure medications for Lennox-Gastaut syndrome.
Brigo F, Jones K, Eltze C, Matricardi S. Brigo F, et al. Cochrane Database Syst Rev. 2021 Apr 7;4(4):CD003277. doi: 10.1002/14651858.CD003277.pub4. Cochrane Database Syst Rev. 2021. PMID: 33825230 Free PMC article.
We found low-certainty evidence that 105 more people per 1000 (CI 17 fewer to 967 more) had AE leading to study discontinuation with add-on rufinamide compared to add-on placebo (one study; 59 participants; RR 4.14, 95% CI 0.49 to 34.86). ...However, we found high-c …
We found low-certainty evidence that 105 more people per 1000 (CI 17 fewer to 967 more) had AE leading to study discontinuation with …
Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials.
Chen Y, Li W, Lu C, Gao X, Song H, Zhang Y, Zhao S, Cai G, Guo Q, Zhou D, Chen Y. Chen Y, et al. EClinicalMedicine. 2024 Feb 28;70:102513. doi: 10.1016/j.eclinm.2024.102513. eCollection 2024 Apr. EClinicalMedicine. 2024. PMID: 38449838 Free PMC article.
METHODS: We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus from their inception until 17 January 2024, evaluating the efficacy, tolerability, and safety of rufinamide (RUF), brivaracetam (BRV), cenobamate (CNB), eslicarbazepine (ESL), …
METHODS: We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus from their inception until 17 January 2024, …
Dramatic weight loss with rufinamide.
Mourand I, Crespel A, Gelisse P. Mourand I, et al. Epilepsia. 2013 Jan;54(1):e5-8. doi: 10.1111/j.1528-1167.2012.03579.x. Epub 2012 Jul 10. Epilepsia. 2013. PMID: 22780580
Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy in the treatment of Lennox-Gastaut syndrome. ...RUF can cause clinically significant weight loss in adult patients, even at low dose. This AE can affect patients who are already underwe …
Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy in the treatment of Lennox-Gastaut syndrome. ...RUF …
Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial.
Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Ohtsuka Y, et al. Epilepsy Res. 2016 Mar;121:1-7. doi: 10.1016/j.eplepsyres.2016.01.002. Epub 2016 Jan 12. Epilepsy Res. 2016. PMID: 26827266 Free article. Clinical Trial.
KEY FINDINGS: Of the 54 patients, 41 (75.9%) completed the extension study. The median duration of exposure to rufinamide was 818.0 days in all 54 patients, and 38 patients (70.4%) received rufinamide for 2 years or more. ...Adverse events resulting in discontinuati …
KEY FINDINGS: Of the 54 patients, 41 (75.9%) completed the extension study. The median duration of exposure to rufinamide was 818.0 d …
The long-term safety of antiepileptic drugs.
Gaitatzis A, Sander JW. Gaitatzis A, et al. CNS Drugs. 2013 Jun;27(6):435-55. doi: 10.1007/s40263-013-0063-0. CNS Drugs. 2013. PMID: 23673774 Review.
Sporadic publications have raised issues about AEs of the newer AEDs eslicarbazepine, retigabine, rufinamide, lacosamide and perampanel but their long-term safety profiles may take years to be fully appreciated. Physicians should not only be aware of the late and chronic A …
Sporadic publications have raised issues about AEs of the newer AEDs eslicarbazepine, retigabine, rufinamide, lacosamide and perampan …
New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?
French JA, Gazzola DM. French JA, et al. Ther Adv Drug Saf. 2011 Aug;2(4):141-58. doi: 10.1177/2042098611411127. Ther Adv Drug Saf. 2011. PMID: 25083209 Free PMC article. Review.
In general, findings from the literature suggest that the newer generation AEDs (including vigabatrin, felbamate, gabapentin, lamotrigine, tiagabine, topiramate, levetiracetam, oxcarbazepine, zonisamide, pregabalin, rufinamide, and lacosamide) enjoy both improved tolerabil …
In general, findings from the literature suggest that the newer generation AEDs (including vigabatrin, felbamate, gabapentin, lamotrigine, t …
Quantitative Cytochrome P450 3A4 Induction Risk Assessment Using Human Hepatocytes Complemented with Pregnane X Receptor-Activating Profiles.
Ekiciler A, Chen WLK, Bo Y, Pugliano A, Donzelli M, Parrott N, Umehara K. Ekiciler A, et al. Drug Metab Dispos. 2023 Mar;51(3):276-284. doi: 10.1124/dmd.122.001132. Epub 2022 Dec 2. Drug Metab Dispos. 2023. PMID: 36460477
Furthermore, the in vivo area under the curve reduction of probe CYP substrates was reasonably predicted for eight marketed drugs (carbamazepine, dexamethasone, enzalutamide, nevirapine, phenobarbital, phenytoin, rifampicin, and rufinamide) using the static net effect mode …
Furthermore, the in vivo area under the curve reduction of probe CYP substrates was reasonably predicted for eight marketed drugs (carbamaze …
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study.
Chin RFM, Pickrell WO, Guelfucci F, Martin M, Holland R. Chin RFM, et al. Seizure. 2021 Oct;91:159-166. doi: 10.1016/j.seizure.2021.05.025. Epub 2021 Jun 9. Seizure. 2021. PMID: 34161904 Free article.
Probable LGS was identified using the International Classification of Diseases-10/Read Code for epilepsy (Hospital Episode Statistics [HES]/CPRD) plus rufinamide prescription. Period prevalence was calculated based on patients enrolled in CPRD GOLD and alive in 2017. ...
Probable LGS was identified using the International Classification of Diseases-10/Read Code for epilepsy (Hospital Episode Statistics [HES]/ …